Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 1,230 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 1,230 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.75, for a total value of $32,902.50. Following the sale, the director owned 23,877 shares of the company’s stock, valued at $638,709.75. The trade was a 4.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Enliven Therapeutics Stock Down 0.6%

Enliven Therapeutics stock opened at $27.03 on Friday. The firm has a market capitalization of $1.60 billion, a P/E ratio of -14.69 and a beta of 0.41. The firm has a fifty day moving average of $20.36 and a 200-day moving average of $20.32. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in shares of Enliven Therapeutics by 30.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company’s stock valued at $508,000 after buying an additional 5,754 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter worth approximately $334,000. Vestal Point Capital LP lifted its holdings in shares of Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after purchasing an additional 910,000 shares during the last quarter. Polar Capital Holdings Plc boosted its position in Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after purchasing an additional 44,713 shares during the period. Finally, Millennium Management LLC grew its stake in Enliven Therapeutics by 19.8% during the 3rd quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock worth $7,807,000 after buying an additional 62,956 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ELVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.